Inactive Instrument

Other languages GOLD SWAP OTC Bulletin Board

Equities

GDSW

US38074W1009

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

23/04	Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	CI
10/04	Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment	23/04
Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University	10/04
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	04/04
Silo Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Silo Pharma, Inc. Exercises Option for Exclusive License Agreement for First-In-Class PTSD and Stress-Induced Anxiety Therapeutic	20/03
Silo Pharma, Inc. Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain	18/03
Silo Pharma?s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery	14/02
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology	01/02
Silo Pharma Announces Positive Results in Alzheimer?s Disease Study	24/01
Silo Pharma, Inc.'s Equity Buyback Plan Extended till March 31, 2024.	09/01
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD	04/01
Silo Pharma, Partner Receive Regulatory Approval to Develop Ketamine Implant for Fibromyalgia Treatment	28/12
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia	28/12
Top Premarket Decliners	20/11
Top Premarket Decliners	17/11
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD	08/11
Silo Pharma?s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis	16/23/16
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA	20/23/20
Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD	12/23/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages GOLD SWAP OTC Bulletin Board

Equities

GDSW

US38074W1009

Other languages

Filters